本帖最后由 老马 于 2012-1-13 21:20 编辑
: V2 C5 l6 @( G/ {0 e: ]- d1 L |2 i3 j/ c8 a5 e ]
爱必妥和阿瓦斯丁的比较
) V! E# ~. P9 l) }
3 R% \# Q0 m# L+ G1 U) t: Bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# w4 E) K% g, V; w0 c" E8 Q1 X
3 P4 h9 ]+ @$ b0 N G% ~& I/ x
2 x& c: k5 }: {, A' \http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 _) ~& C* X' d. s% I2 w1 A2 `
==================================================) U5 O, ~. X9 H, g; \
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
8 G; i% p* v6 M% U2 G- kPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ H4 e/ s3 j8 YResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.1 }, D+ H- P3 K' N5 |( y$ Y. ], N/ y
|